# BostonGene

> BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.

- **Founded:** 2015
- **Headquarters:** Waltham, Massachusetts, United States
- **Founders:** Andrew Feinberg (Co-founder, President & CEO)
- **Team size:** ~420 employees
- **Products:** Tumor Portrait Test, Multiomics Analytics Platform, Biopharma / Drug Development Services, Digital Pathology & Immune Profiling
- **Notable:** Reached unicorn status with a $1B+ valuation in 2022, Received Frost & Sullivan's 2025 Global Technology Innovation Leadership Recognition in AI-driven precision oncology, Published a landmark study providing clinical and analytical validation for its multimodal RNA and DNA assay

## Products & services

- **Tumor Portrait Test** — A tumor-normal assay integrating DNA and RNA sequencing with tumor mutational burden, PD-L1 expression, gene signatures and tumor microenvironment subtyping into a single multimodal test that guides treatment decisions for advanced solid tumors.
- **Multiomics Analytics Platform** — An AI-powered computational platform that decodes patients' molecular profiles, immune system and tumor microenvironment to identify disease drivers and novel drug targets.
- **Biopharma / Drug Development Services** — Biomarker discovery, patient stratification, and clinical-trial optimization services for pharmaceutical partners using BostonGene's molecular and immune profiling.
- **Digital Pathology & Immune Profiling** — Multiplex immunofluorescence imaging, flow cytometry and spatial analysis characterizing the tumor immune microenvironment.

## Achievements

- Reached unicorn status with a $1B+ valuation in 2022
- Received Frost & Sullivan's 2025 Global Technology Innovation Leadership Recognition in AI-driven precision oncology
- Published a landmark study providing clinical and analytical validation for its multimodal RNA and DNA assay
- Co-developed a small cell lung cancer assay with AstraZeneca and MD Anderson now used in a national study
- Established a global partnership and joint venture with NEC to expand into Asian markets

## Latest updates

- **2025-08** — Featured in a Frost & Sullivan report and recognized for 2025 Global Technology Innovation Leadership in AI-driven precision oncology.
- **2025-04** — Released an updated Tumor Portrait test report integrating multimodal DNA and RNA profiling.
- **2025-01** — Announced collaborations with AstraZeneca and Ottimo Pharma advancing AI-driven, foundation-model oncology development.
- **2024-01** — Published landmark clinical and analytical validation study for its multimodal RNA and DNA assay.

## Links

- Website: https://bostongene.com
- LinkedIn: https://www.linkedin.com/company/bostongene
- Twitter/X: https://twitter.com/BostonGeneCorp
- YouTube: https://www.youtube.com/channel/UCvu9tWwr-xyI1O9QM314NCw
- Instagram: https://www.instagram.com/bostongenecorp/
- Facebook: https://www.facebook.com/BostonGeneCorp

---

Profile page: https://yespress.io/bostongene
Published by YesPress — https://yespress.io
Last updated: 2026-07-22